Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Adamax Results Timeline: Research Phase Comparison

Days 1–7 AMPK phosphorylation begins; transient RQ shift from 0.85 to 0.78 Subtle thermogenesis increase; inconsistent appetite modulation Initial ACC inhibition; early fatty acid oxidation signaling Acute response only. Not predictive of long-term outcome; do

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Days 1–7
  • AMPK phosphorylation begins; transient RQ shift from 0.85 to 0.78
  • Subtle thermogenesis increase; inconsistent appetite modulation
  • Initial ACC inhibition; early fatty acid oxidation signaling
  • Acute response only. Not predictive of long-term outcome; do not judge protocol success here
  • Weeks 2–4
  • PGC-1α activation; mitochondrial biogenesis initiation
  • Improved workout endurance; reduced post-meal energy crash; earlier satiety onset
  • Mitochondrial DNA replication; enhanced leptin receptor sensitivity
  • Metabolic machinery is being constructed. Body composition changes minimal but metabolic foundation is critical
  • Weeks 5–8
  • Mitochondrial density increase; stable fat oxidation preference
  • Visible body recomposition; visceral fat reduction on DEXA despite stable scale weight
  • Receptor sensitization; self-sustaining AMPK activity at lower peptide dose
  • Peak visual and performance improvement window. This is when most meaningful changes become apparent
  • Weeks 9–12+
  • Insulin sensitivity improvement; metabolic adaptation plateau
  • Performance markers stabilize; further composition changes slow
  • Steady-state AMPK pathway operation; structural metabolic reprogramming complete
  • Maintenance phase. Continued dosing sustains adapted state; escalation yields diminishing returns
  • The comparison makes clear that expecting Phase 3 outcomes during Phase 1 is a biological impossibility. The metabolic processes governing each phase require time-dependent cellular adaptations that cannot be compressed through dose escalation or adjunct interventions. They unfold according to gene transcription timelines and protein synthesis rates that are fixed biological constants.